Zopiclone

Generic Name: Zopiclone

Brand Names: Imovane

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇ClN_₆O_₃

CAS Number: 43200-80-2

Unique Ingredient Identifier: 03A5ORL08Q

Background: Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

Indication: For the short-term treatment of insomnia.

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Hot Flashes

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo to elinzanetant
Drug: Zopiclone
Drug: Placebo to zopiclone

First Posted Date: 2024-01-23

Last Posted Date: 2024-05-08

Lead Sponsor: Bayer

Target Recruit Count: 64

Registration Number: NCT06219902

Locations: 🇨🇦
AltaSciences, Mount-Royal, Canada

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: TS-142
Drug: Zopiclone

First Posted Date: 2023-04-19

Last Posted Date: 2023-09-05

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 43

Registration Number: NCT05819710

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: TS-142
Drug: Zopiclone
Drug: Placebo

First Posted Date: 2021-01-06

Last Posted Date: 2022-10-06

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 61

Registration Number: NCT04696952

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Seltorexant Dose 1
Drug: Seltorexant Dose 2
Drug: Placebo
Drug: Zopiclone

First Posted Date: 2020-06-30

Last Posted Date: 2023-03-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 63

Registration Number: NCT04451187

Locations: 🇧🇪
Anima, Alken, Belgium
🇩🇪
Universitaetsklinikum der RWTH Aachen, Aachen, Germany

Hangover and Residual Zopiclone Effect on Spatial Perception

Phase 1

Conditions: Healthy
Alcohol Drinking

First Posted Date: 2018-08-15

Last Posted Date: 2018-08-15

Lead Sponsor: Petri Vainio

Target Recruit Count: 16

Registration Number: NCT03632408

Locations: 🇫🇮
Teutori clinical trial facility, Turku, Finland

Efficacy of Multimodal Analgesia Following Hip Arthroscopy

Not Applicable

Completed

Conditions: Hip Pain Chronic

Interventions: Drug: Percocet
Drug: Zopiclone
Drug: Gabapentin
Drug: Celebrex
Drug: Naprosyn

First Posted Date: 2017-11-22

Last Posted Date: 2021-10-15

Lead Sponsor: Western University, Canada

Target Recruit Count: 100

Registration Number: NCT03351439

Locations: 🇨🇦
Fowler Kennedy Sport Medicine Clinic, London, Ontario, Canada

Effectiveness of BBT-I and Zopiclone for Chronic Insomnia

Phase 2

Completed

Conditions: Insomnia Chronic

Interventions: Behavioral: Brief behavioral therapy
Drug: Zopiclone

First Posted Date: 2017-11-13

Last Posted Date: 2019-09-16

Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Target Recruit Count: 42

Registration Number: NCT03339583

Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance

Phase 4

Terminated

Conditions: Ventricular Dysfunction
Sleep Apnea, Central

Interventions: Drug: Placebo
Drug: Zopiclone

First Posted Date: 2016-07-01

Last Posted Date: 2021-05-26

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 2

Registration Number: NCT02820441

Locations: 🇫🇷
Clinique de Physiologie Sommeil et Exercice, Pole Thorax et Vaisseaux , University Hospital Grenoble Alpes, Grenoble, France

Pharmacological Treatment of Insomnia in Palliative Care

Phase 4

Completed

Conditions: Sleep
Insomnia

Interventions: Drug: Placebo
Drug: Zopiclone

First Posted Date: 2016-06-21

Last Posted Date: 2021-07-16

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 43

Registration Number: NCT02807922

Locations: 🇳🇴
sykehuset Levanger, Levanger, Norway
🇳🇴
St. Olavs Hospital, Trondheim, Norway
🇳🇴
Helse Sør-Øst RHF, Sykehuset i Vestfold,, Tønsberg, Norway

and more 2 locations

SleepSure: A Trial to Assess the Effects of Eye Masks and Earplugs on Hospital Inpatient Sleep

Phase 3

Completed

Conditions: Sleep

Interventions: Device: Ear plugs
Drug: Zopiclone
Device: Eye Mask

First Posted Date: 2016-04-11

Last Posted Date: 2019-10-01

Lead Sponsor: Oxford University Hospitals NHS Trust

Target Recruit Count: 206

Registration Number: NCT02732912

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy